The Supreme Court seemed torn Monday over whether a federal drug labeling law should pre-empt a $7 million verdict in the case of a woman who lost an arm to gangrene after being given a Wyeth drug for a migraine. Wyeth v. Levine has been billed as a milestone in industries' effort to free themselves of state court tort litigation by embracing a single federal regulatory regime. But based on the argument, the case could be decided narrowly, giving little guidance about broader pre-emption issues.
High Court Appears Torn Over Drug Labeling Case
November 4, 2008